1.
Marijuana school opens in Michigan
Monday, November 30
|
|
|
| Panacos Pharmaceuticals, Inc. Add to My Watchlist | (OTCPK: PANC) |
| Panacos | 0.02 | +0.00 (+1.90%) | 81,440 |
| Profile for PANC |
|
Panacos Pharmaceuticals, Inc. 134 Coolidge Avenue Watertown, MA 02472 http://www.vitechnologies.com |
|
|
Panacos Pharmaceuticals is a development-stage biotechnology company that seeks to develop anti-infective products through the discovery and development of small-molecule oral drugs designed to treat human immunodeficiency virus (HIV) and other major human viral diseases. Co.'s lead product candidate, bevirimat, is a once-daily oral HIV drug candidate in Phase 2 clinical testing. Co. also has research and development programs designed to generate second- and third-generation maturation inhibition products and a research and development program focused on an early step in the HIV virus life cycle, fusion of the HIV virus to human cells. |
|
| Headquarters for PANC |
| Key Facts |
|
|
|
||
| Mr. Jeremy Hayward-Surry | Chairman | |
| Dr. Alan W. Dunton M.D. | Chief Executive Officer; President | |
| Ms. Jane Pritchett Henderson | Chief Financial Officer; Executive Vice President; Chief Business Officer; Secretary | |
| Mr. Scott McCallister M.D. | Chief Medical Officer | |
| Dr. Graham P. Allaway Ph.D. | Chief Operating Officer | |
| Mr. Robert B. Pelletier | Principal Accounting Officer; Vice President | |
| Dr. David E. Martin Pharm.D. | Senior Vice President | |
| Mr. Frederick Schmid | Senior Vice President | |
| Dr. Tom Lategan D.Phil. | Vice President | |
| Dr. John D. Richards D.Phil. | Vice President | |
E-mail Article to a Friend
Most Popular
Stories
Photos
Videos
People
Monday, November 30
Monday, November 30
Monday, November 30
